CANINE COMPARATIVE ONCOLOGY & GENOMICS CONSORTIUM

Re-organization of the CCOGC

During re-organization of the CCOGC we are suspending tissue sales. Please check back for further information on the bank status and tissue releases. We will however make matched blood and frozen tumor/normal tissues available to successful applicants to the recent P30 Cancer Center Call at no charge. We will not be able to provide slides from any samples as these require further processing and would incur a cost. Please note we are unable to guarantee the availablity of requested samples. To obtain a letter of support and a list of available samples for your application please submit your request by email to the CCOGC at administration@ccogc.net Please allow 10 business days for a response.

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium and the Pfizer-CCOGC Biospecimen Repository Announces the ACCELERATED DISTRIBUTION of Biospecimen Samples

The Pfizer-CCOGC Biospecimen Repository has been open for release since September 2013. As part of its strategic effort to accelerate discovery, the Pfizer-CCOGC Biospecimen Repository has modified the process of biospecimen sample release and distribution. Most applications will no longer require scientific review or project disclosure. CCOCG President, Dr. Jaime Modiano said, “our experience to date indicates that investigators soliciting samples are conducting highly meritorious projects, and the results generated from these samples have led to important publications which have had significant, positive impact in the fields of cancer and genomics. To continue and expand these trends, we have streamlined the application process to make our high quality biospecimens more accessible and to make their release expeditious.” Quality control and assessment indicates that diagnostic accuracy for samples in the Pfizer-CCOGC Biospecimen Repository is exceptional, supporting high quality downstream applications for pathologic, genomic, and other analyses. The Pfizer-CCOGC Biospecimen Repository houses over 60,000 samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium and the Pfizer-CCOGC Biospecimen Repository Announces the Sale of 1000 Biospecimens in First Year and Completion of Quality Control and Assessment of Repository

Rockville, MD – The Pfizer-CCOGC Biospecimen Repository has been open for release since September 2013. In year one, the Pfizer-CCOGC Biospecimen Repository has sold 1000 samples to investigators. Each application is evaluated based on scientific merit. Quality control and assessment of randomly selected samples from the Pfizer-CCOGC Biospecimen Repository, representing 10% of all cases submitted, has been completed.  The diagnostic classification of almost 89% of submitted specimens was corroborated by in-depth re-review by a panel of independent veterinary pathologists. Secondly, the proportion of specimens yielding nucleic acid considered being of suitable quality for most downstream genomics applications was 89.4% for tumor DNA, 92.1% for tumor RNA and 99.5% for blood DNA. The Pfizer-CCOGC Biospecimen Repository currently houses over 60,000 samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and hemangiosarcoma. Samples available from each patient include: tumor and normal tissues (formalin fixed, snap frozen and OCT), as well as frozen serum, plasma, urine and whole blood (from both EDTA and PaxGene RNA

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium and the Pfizer-CCOGC Biospecimen Repository Announce the Availability of Canine Cancer Patient Biospecimens for Scientific Study Effective October 29th 2012

Rockville, MD – Canine cancer patient biospecimens are now available for scientific use through the Canine Comparative Oncology and Genomics Consortium (CCOGC) and the Pfizer-CCOGC Biospecimen Repository. The CCOGC has created an infrastructure for the collection and banking of tissues from dogs with naturally occurring cancer to help researchers further the investigation into the inner workings of cancer in the domestic dog, as well as facilitate investigation into tumor types with broad translational relevance that can benefit both human and dog patients. The Pfizer-CCOGC Biospecimen Repository currently houses over 2,000 patient samples across seven spontaneously arising cancer histologies: osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas and hemangiosarcoma. Samples available from each patient include: tumor and normal tissues (formalin fixed, snap frozen and OCT), as well as frozen serum, plasma, urine and whole blood (from both EDTA and PaxGene RNA collection tubes). For more information about CCOGC and to apply for samples from the biorepository, please visit www.ccogc.net or contact us at biospecimens@ccogc.net CCOGC Background Formed in 2004,

Click Here to Read More

Pfizer-CCOGC Biospecimen Repository is open as of October 29th 2012

Canine cancer patient biospecimens are now available for scientific use through the Canine Comparative Oncology and Genomics Consortium (CCOGC) and the Pfizer-CCOGC Biospecimen Repository. Please click here for the associated news release. The Pfizer-CCOGC Biospecimen Repository currently houses over 2,000 patient samples across the following seven spontaneously arising cancer histologies: lymphoma osteosarcoma melanoma pulmonary tumors mast cell tumors soft tissue sarcomas hemangiosarcoma Samples available from each patient include: tumor and normal tissues (formalin fixed, snap frozen and OCT), as well as frozen serum, plasma, urine and whole blood (from both EDTA and PaxGene RNA collection tubes). The price of each specimen is availble by clicking on each of the histology names above. Click here to be redirected to the application site. There is an administration fee for each application.  Once we receive the application, it will be checked for completeness prior to being processed through a series of reviews. Upon approval, the tissues will be issued. For all questions about specimens, current specimen pricing and the application process please contact us by e-mail at biospecimens@ccogc.net

Click Here to Read More

Canine Comparative Oncology and Genomics Consortium And the Pfizer-CCOGC Biospecimen Repository Announce the Availability of Canine Biospecimens for Scientific Study

Rockville, MD – Canine cancer biospecimens are now available to be released for scientific research through the Canine Comparative Oncology and Genomics Consortium (CCOGC) and the Pfizer-CCOGC Biospecimen Repository. Patient sample sets from canine cancer patients have been collected to build the repository and they are now available to help researchers further the investigation into the inner workings of cancer in many breeds, as well as facilitate investigation into tumor types with broad translational relevance that can benefit both human and veterinary patients. Seven spontaneously arising cancer histologies (osteosarcoma, lymphoma, melanoma, pulmonary tumors, mast cell tumor, soft tissue sarcomas, hemangiosarcom) are currently banked.  Samples from each patient include: tumor tissue, normal tissue, serum, plasma, urine, whole blood, DNA, and RNA. In addition, the CCOGC has an established infrastructure for prospective sample collection should the banked samples not meet your research needs. For more information about CCOGC, applying for repository samples, or inquiring about prospective tissue collections, please visit our website at www.ccogc.net or contact us at administration@ccogc.net. CCOGC Background Formed in

Click Here to Read More

Prospective collections now available

In 2007 sample collection began at three veterinary institutions, with a focus on collecting three histologies of interest in the field of comparative oncology (osteosarcoma, lymphoma, melanoma). In 2008, four additional collection sites were added plus four additional histologies. In accordance with the initial goals of the CCOGC, the prospective collection of tissues is now available. By making use of the existing CCOCG Biorepository infrastructure, investigators can have biospecimens collected to their specifications for unique research needs.

Click Here to Read More